Presage Adds $1.5M

8/10/11

Seattle-based Presage Biosciences, a spinoff from the Fred Hutchinson Cancer Research Center, has raised $1.6 million out of a new equity financing that could be worth as much as $10.5 over time, according to a regulatory filing. The document doesn’t say who is backing the company, although it says the round includes 20 investors. Presage, which has previously raised at least $4 million, has developed a tool that drugmakers are using to get a better sense of which experimental drugs are likely to succeed in clinical trials.

By posting a comment, you agree to our terms and conditions.